Compare Citius Pharmaceuticals Inc (CTXR) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs General Dynamics Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while General Dynamics Corporation trades at $331.32 (market cap $88.37B). The key difference: General Dynamics Corporation is far larger — about 6408.3× Citius Pharmaceuticals Inc's market cap, and General Dynamics Corporation pays a 1.95% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and General Dynamics Corporation for 85 Days on average.
| CTXR | GD | |
|---|---|---|
Market Cap | $13.79M | $88.37B |
Volume | 156,684 | 1,251,409 |
Sector | Health | Industrials |
52-Week High | $1.82 | $395.97 |
52-Week Low | $0.48 | $312.53 |
Typical Hold Time | 16 Days | 85 Days |
Enterprise Value | $3.96M | $93.52B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
General Dynamics (GD) trades at $329.90, down 0.43% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, while technical indicators show oversold conditions with RSI at 11.03.
GD offers solid value with reasonable valuation multiples and strong defense contract visibility, though near-term technical weakness and dependence on government spending create volatility. The stock's 27% upside to consensus target and consistent dividend payments provide attractive total return potential for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
